Neutral alpha-glucosidase was isolated from rat liver by Sephadex G-150 gel filtration and polyacrylamide gel electrophoresis at pH 8.9. The enzyme was found to exist in two major forms: alpha-glucosidase AB and alpha-glucosidase C. The neutral alpha-glucosidase C was purified to apparent homogeneity and biochemically characterized. The enzyme form accounts for 25-30% of the total enzyme activity, has a pH optimum at 6.0-6.5 and is thermostable. The apparent Km values for alpha-glucosidase C with maltose, MUF-alpha-D-glucopyranoside and glycogen as substrates were 1.22 mM, 0.47 mM and 68.9 mg, respectively. The finding that glycogen can serve as substrate for neutral alpha-glucosidase C suggests its involvement in glycogen metabolism.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents.
Future Med Chem
January 2025
Chemistry Department, Faculty of Science, Arish University, Arish, Egypt.
Background: Using an analogue-based drug design approach, a number of novel 2-substituted-1,3-thiazolone derivatives (3-10) have been produced and given permission to proceed for their anti-inflammatory properties. In the present paper, the new thiazole derivatives were designed, synthesized, and tested for their alpha-glucosidase, alpha-amylase, and COX-inhibitory activities. Approving the anti-diabetic activity.
View Article and Find Full Text PDFSubstituted piperazine conjugated to quinoline-thiosemicarbazide as potent α-glucosidase inhibitors to target hyperglycemia.
Sci Rep
January 2025
Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P. O. Box 33, Nizwa, Oman.
Diabetes mellitus, particularly type 2 diabetes, is a growing global health challenge characterized by chronic hyperglycemia due to insulin resistance. One therapeutic approach to managing this condition is the inhibition of α-glucosidase, an enzyme involved in carbohydrate digestion, to reduce postprandial blood glucose levels. In this study, a series of thiosemicarbazide-linked quinoline-piperazine derivatives were synthesized and evaluated for their α-glucosidase inhibitory activity, to identify new agents for type 2 diabetes management.
View Article and Find Full Text PDFInhibition of acrylamide and α-amylase and α-glucosidase activities in Echium amoenum powder fortified biscuits.
Food Res Int
January 2025
Department of Food Science and Technology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran.
Echium amoenum (borage) powder (EAP) is consumed traditionally and is known to possess health-promoting effects. In this research, application of Echium amoenum (borage) powder (EAP) at levels of zero, 1 and 2 % w/w was investigated in the production of biscuit as a widely consumed snack and some characteristics of dough and biscuit samples were evaluated. By adding EAP and increasing its level, water absorption values and dough stability increased (p < 0.
View Article and Find Full Text PDFStructure identification of myricetin-phenylacetaldehyde adducts and their potential biological activities.
Food Res Int
January 2025
School of Food Science and Engineering, Ministry of Education Engineering Research Center of Starch and Protein Processing, Guangdong Province Key Laboratory for Green Processing of Natural Products and Product Safety, South China University of Technology, Guangzhou 510640, China; Modern Industrial Technology Research Institute, South China University of Technology, Zhongshan 528437, China. Electronic address:
Our previous research discovered that myricetin could effectively inhibit the formation of heterocyclic aromatic amines (HAAs) in cantonese baked foods by trapping phenylacetaldehyde to form adducts. However, the structure and biological activity of these adducts were still unknown. In this study, we identified two myricetin-phenylacetaldehyde adducts from cantonese mooncakes, BYQ-2 and BYQ-3, using pre-HPLC.
View Article and Find Full Text PDFChallenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.
J Neurol
January 2025
John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle-upon-Tyne, UK.
PROPEL (ATB200-03; NCT03729362) compared the efficacy and safety of cipaglucosidase alfa plus miglustat (cipa + mig), a two-component therapy for late-onset Pompe disease (LOPD), versus alglucosidase alfa plus placebo (alg + pbo). The primary endpoint was change in 6-min walk distance (6MWD) from baseline to week 52. During PROPEL, COVID-19 interrupted some planned study visits and assessment windows, leading to delayed visits, make-up assessments for patients who missed ≥ 3 successive infusions before planned assessments at weeks 38 and 52, and some advanced visits (end-of-study/early-termination visits).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!